NASDAQ$BEAM
Beam Therapeutics Inc. · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Pipeline and business highlights were announced and financial results were reported.
Beam Therapeutics reported its Q2 2022 financial results, including cash, cash equivalents and marketable securities of $1.2 billion. The company is on track for patient enrollment in the BEACON Phase 1/2 trial of BEAM-101 in the second half of 2022. The IND for BEAM-201 was submitted to the FDA but is currently on clinical hold.
- Patient enrollment into BEACON Phase 1/2 Trial of BEAM-101 on track for second half of 2022.
- BEAM-201 IND Submitted to FDA; Currently on Clinical Hold.
- BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022.
- Ended Second Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities.
Headline financials
Revenue & EPS history
Beam Therapeutics · Revenue · Quarterly
$16.7M
Revenue by segment
Beam Therapeutics · $6K total across 1 segment · Q2 2021
- License & collaboration revenue$6K—100.0%
Forward guidance
Beam Therapeutics anticipates nominating additional development candidates, initiating IND-enabling studies, submitting IND applications, and initiating clinical trials. The company expects to expand its portfolio with clinical and preclinical milestones in the coming quarters.
Tailwinds
- On track to begin patient enrollment in BEACON trial in the second half of 2022.
- Plans to submit IND application for BEAM-102 in the second half of 2022.
- BEAM-301 is on track for initiation of IND-enabling studies in the second half of 2022.
- Anticipates the nomination of a second liver-targeted development candidate in 2022.
- Developed a potentially non-genotoxic approach that combines antibody-based conditioning with multiplex gene-edited hematopoietic stem cells.
Headwinds
- Received notification from the FDA of a clinical hold on the IND for BEAM-201.
- Does not expect to nominate a second CAR-T development candidate in 2022.
- Uncertainty in the outcome of interactions with the FDA regarding the clinical hold on the BEAM-201 IND.
- The FDA indicated it will provide an official clinical hold letter to Beam within 30 days.
- Clinical hold on BEAM-201 IND
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.6%
Avg return
30 days after
56%
14 / 25 earnings
Positive
+21.8%
Q4 2023
Best reaction
-11.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -2.4% | -9.3% | |
| Q4 2025 | +14.1% | +0.5% | -16.6% | |
| Q3 2025 | -6.4% | -8.4% | +19.2% | |
| Q1 2025 | +3.9% | -0.2% | -1.1% | |
| Q4 2024 | -3.1% | -14.5% | -27.9% | |
| Q3 2024 | +9.3% | +11.1% | +3.9% | |
| Q2 2024 | -4.5% | -4.5% | -5.6% | |
| Q1 2024 | -2.4% | -6.7% | +5.7% | |
| Q4 2023 | +21.8% | +11.3% | -7.7% | |
| Q3 2023 | -11.1% | -12.2% | +5.6% | |
| Q2 2023 | +2.2% | +0.0% | -1.5% | |
| Q1 2023 | +1.9% | +4.3% | -6.7% | |
| Q4 2022 | -1.3% | +0.3% | -22.7% | |
| Q3 2022 | -10.3% | +19.0% | +3.0% | |
| Q2 2022 | +3.2% | +8.5% | -10.4% | |
| Q1 2022 | +0.3% | -0.6% | +12.6% | |
| Q4 2021 | -1.7% | -14.3% | -20.5% | |
| Q3 2021 | +9.1% | +2.9% | -11.4% | |
| Q2 2021 | +1.0% | -5.6% | +1.0% | |
| Q1 2021 | +4.3% | +12.2% | +37.1% | |
| Q4 2020 | -4.4% | -5.6% | -22.3% | |
| Q3 2020 | +2.5% | -1.4% | +109.9% | |
| Q2 2020 | -5.1% | -3.5% | +8.6% | |
| Q1 2020 | +3.3% | +3.4% | +23.1% | |
| Q4 2019 | +3.3% | +3.4% | +23.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro